Who are Fluocinolone Acetonide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Emflaza, Arnuity Ellipta, Lotemax, Pandel, Flonase, Pulmicort Respules.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fluocinolone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Fluocinolone Acetonide — Competitive Intelligence Brief

Fluocinolone Acetonide (FLUOCINOLONE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroid [EPC]. Area: Immunology.

marketed Corticosteroid [EPC] Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Fluocinolone Acetonide (FLUOCINOLONE) — Eurofarma.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fluocinolone Acetonide TARGET	FLUOCINOLONE	Eurofarma	marketed	Corticosteroid [EPC]		2016-01-01
Emflaza	DEFLAZACORT	Ptc Therap	marketed	Corticosteroid [EPC]		2017-01-01
Arnuity Ellipta	FLUTICASONE FUROATE	Haleon Us Holdings	marketed	Corticosteroid	Glucocorticoid receptor	2007-01-01
Lotemax	LOTEPREDNOL ETABONATE	Bausch Health	marketed	Corticosteroid	Glucocorticoid receptor	1998-01-01
Pandel	HYDROCORTISONE PROBUTATE	ANI Pharmaceuticals	marketed	Corticosteroid	Glucocorticoid receptor	1997-01-01
Flonase	fluticasone propionate	GSK (GlaxoSmithKline)	marketed	Inhaled/intranasal corticosteroid	Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor	1994-11-04
Pulmicort Respules	BUDESONIDE	AstraZeneca K.K.	marketed	Corticosteroid [EPC]	Glucocorticoid receptor	1994-01-01

Recent regulatory actions (last 90 days)

2026-03-03 — Flonase · FDA · approved · US · GSK (GlaxoSmithKline)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-08-26 — Flonase · 7500444*PED · Compound · US
2026-11-09 — Pulmicort Respules · 11413296 · Formulation · US
2026-11-09 — Pulmicort Respules · 11197822 · Formulation · US
2026-11-09 — Pulmicort Respules · 8975243 · Method of Use · US
2026-11-09 — Pulmicort Respules · 9119863 · Method of Use · US
2026-11-09 — Pulmicort Respules · 8679545 · Formulation · US
2026-11-09 — Pulmicort Respules · 8497258 · Method of Use · US
2028-11-12 — Pulmicort Respules · 11357859 · Method of Use · US
2028-11-22 — Pulmicort Respules · 10293052 · Formulation · US
2029-05-07 — Pulmicort Respules · 8491932 · Formulation · US
2029-08-01 — Pulmicort Respules · 9050368 · Formulation · US
2029-08-03 — Pulmicort Respules · 8324192 · Method of Use · US
2031-02-14 — Flonase · 10195375 · Formulation · US
2031-04-04 — Flonase · 12083270 · Method of Use · US
2031-08-14 — Flonase · 10195375*PED · Compound · US
2031-09-07 — Pulmicort Respules · 8895064 · Formulation · US
2031-09-07 — Pulmicort Respules · 9132093 · Formulation · US
2031-09-07 — Pulmicort Respules · 9192581 · Formulation · US
2031-09-07 — Pulmicort Respules · 10660858 · Formulation · US
2031-09-07 — Pulmicort Respules · 10307375 · Formulation · US
2033-05-03 — Lotemax · 10993908 · Method of Use · US
2033-05-03 — Lotemax · 9532955 · Method of Use · US
2033-05-03 — Lotemax · 10058511 · Formulation · US
2033-05-03 — Lotemax · 11219596 · Method of Use · US
2033-05-03 — Lotemax · 11219597 · Method of Use · US
2033-05-03 — Lotemax · 11596599 · Method of Use · US
2033-05-03 — Lotemax · 10857096 · Method of Use · US
2033-05-03 — Lotemax · 10864219 · Method of Use · US
2033-05-03 — Lotemax · 10945948 · Method of Use · US
2033-05-03 — Lotemax · 10940108 · Method of Use · US

Sponsor landscape (Corticosteroid [EPC] class)

Eurofarma · 2 drugs in this class
· 2 drugs in this class
Astellas Pharma · 1 drug in this class
AstraZeneca K.K. · 1 drug in this class
Generic (originally Merck) · 1 drug in this class
Generic (originally Merck/Upjohn) · 1 drug in this class
Generic (originally Schering) · 1 drug in this class
National Jewish Health · 1 drug in this class
Padagis Us · 1 drug in this class
Ptc Therap · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fluocinolone Acetonide — Competitive Intelligence Brief. https://druglandscape.com/ci/fluocinolone. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab